EW Edwards Lifesciences Corp
Orthopedic, Prosthetic & Surgical Appliances & Supplies · NYSE · SEC CIK 1099800 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY13.4%
TTM net income YoY-25.3%
TTM EPS YoY-23.7%
Revenue 3-yr CAGR9.4%
Net income 3-yr CAGR-10.6%
Margins
Gross margin78.0%
Operating margin21.6%
Net margin15.3%
FCF margin21.3%
EBITDA margin24.2%
Returns
ROE9.7%
ROA7.5%
ROIC (approx.)12.1%
Asset turnover0.49x
Leverage & solvency
Liabilities / assets22.5%
Debt / equity0.06x
Current ratio4.60x
Interest coverage—
Cash quality & payout
Operating cash flow / net income1.68x
Accruals ratio-5.1%
Payout ratio—
Capex / revenue4.4%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q42024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $1.72B | $1.74B | $1.65B | $1.57B | $1.55B | $1.53B | $1.41B | $1.39B |
| Cost of revenue | $369.20M | $392.40M | $362.60M | $343.00M | $345.20M | $344.40M | $301.60M | $292.20M |
| Gross profit | $1.35B | $1.35B | $1.29B | $1.23B | $1.21B | $1.19B | $1.11B | $1.09B |
| R&D expense | $281.40M | $278.90M | $263.30M | $267.70M | $280.70M | $276.20M | $254.60M | $271.10M |
| SG&A expense | $560.90M | $561.20M | $522.20M | $602.90M | $514.60M | $502.00M | $465.70M | $491.90M |
| Operating income | $299.10M | $513.20M | $477.60M | $151.10M | $307.10M | $411.20M | $394.80M | $312.60M |
| Pretax income | $363.20M | $519.80M | $459.00M | $90.40M | $348.40M | $400.20M | $433.90M | $390.10M |
| Income tax | $61.80M | $278.40M | $78.30M | $26.20M | $56.10M | $64.30M | $70.30M | $45.10M |
| Net income | $307.50M | $241.90M | $380.70M | $91.20M | $291.10M | $333.20M | $358.00M | $385.60M |
| EBITDA | $344.00M | $555.90M | $518.50M | $193.80M | $346.30M | $449.30M | $431.40M | $355.20M |
| EPS (basic) | 0.53 | 0.42 | 0.66 | — | 0.50 | 0.57 | 0.61 | 0.65 |
| EPS (diluted) | 0.53 | 0.42 | 0.66 | — | 0.50 | 0.56 | 0.61 | 0.65 |
| Weighted avg. shares (diluted) | 577.60M | 577.60M | 580.70M | — | 585.70M | 587.90M | 587.80M | — |
| Banking | ||||||||
| Net interest income | $36.50M | $30.00M | $33.50M | -$132.90M | $38.60M | $37.40M | $36.50M | -$76.10M |
| Balance sheet | ||||||||
| Cash & equivalents | $3.11B | $2.91B | $2.45B | $2.94B | $2.69B | $3.29B | $3.15B | $3.06B |
| Short-term investments | $1.53B | $1.35B | $1.23B | $1.29B | $1.16B | $789.40M | $757.90M | $930.70M |
| Receivables | $784.90M | $770.40M | $775.70M | $659.60M | $693.30M | $697.00M | $669.20M | $609.10M |
| Inventory | $1.16B | $1.13B | $1.12B | $1.13B | $1.14B | $1.14B | $1.11B | $1.09B |
| Current assets | $7.25B | $6.82B | $6.23B | $6.74B | $6.36B | $6.58B | $6.21B | $6.29B |
| PP&E, net | $1.86B | $1.84B | $1.82B | $1.81B | $1.74B | $1.73B | $1.70B | $1.69B |
| Goodwill | $1.95B | $1.95B | $1.82B | $1.77B | $1.77B | $1.78B | $1.78B | $1.78B |
| Intangibles | $1.16B | $1.38B | $1.23B | $1.13B | $1.13B | $1.17B | $1.17B | $1.18B |
| Total assets | $14.14B | $13.87B | $13.32B | $13.70B | $13.27B | $13.49B | $13.02B | $13.06B |
| Current liabilities | $1.58B | $1.51B | $1.41B | $1.81B | $1.59B | $1.40B | $1.39B | $1.51B |
| Long-term debt | $598.80M | $598.70M | $598.50M | $598.30M | $598.20M | $598.00M | $597.80M | $597.70M |
| Total debt | $598.80M | $598.70M | $598.50M | $598.30M | $598.20M | $598.00M | $597.80M | $597.70M |
| Total liabilities | $3.18B | $3.14B | $2.99B | $3.36B | $3.07B | $2.88B | $2.83B | $2.99B |
| Shareholders' equity | $10.86B | $10.62B | $10.33B | $10.34B | $10.21B | $10.55B | $10.13B | $10.00B |
| Net debt | -$2.51B | -$2.31B | -$1.85B | -$2.34B | -$2.10B | -$2.69B | -$2.55B | -$2.46B |
| Shares outstanding | 575.60M | 576.60M | 577.00M | 580.70M | 580.70M | 587.90M | 586.20M | 588.60M |
| Cash flow statement | ||||||||
| Operating cash flow | $570.30M | $651.90M | $43.80M | $450.90M | $573.70M | $290.20M | $280.40M | -$127.50M |
| Capital expenditure | $63.60M | $66.90M | $64.90M | $97.40M | $57.50M | $49.30M | $56.00M | $49.80M |
| Free cash flow | $506.70M | $585.00M | -$21.10M | $353.50M | $516.20M | $240.90M | $224.40M | -$177.30M |
| Investing cash flow | -$256.40M | -$193.20M | -$92.80M | -$198.30M | -$427.80M | -$172.10M | $85.30M | -$576.70M |
| Financing cash flow | -$100.80M | -$300,000 | -$451.20M | -$11.40M | -$740.10M | $52.70M | -$258.00M | $28.60M |
| Depreciation & amortization | $44.90M | $42.70M | $40.90M | $42.70M | $39.20M | $38.10M | $36.60M | $42.60M |
| Stock-based compensation | $46.00M | $42.20M | $45.40M | $39.20M | $41.10M | $37.50M | $40.20M | $31.70M |
| Share buybacks | $138.90M | $153.30M | $421.80M | $40.60M | $588.70M | $5.50M | $258.60M | $100.10M |
Free plan shows the latest 8 periods; Pro shows all 71 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.